<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">21993685</PMID>
<DateCompleted>
<Year>2012</Year>
<Month>05</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1592-8721</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>97</Volume>
<Issue>1</Issue>
<PubDate>
<Year>2012</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Haematologica</Title>
<ISOAbbreviation>Haematologica</ISOAbbreviation>
</Journal>
<ArticleTitle>Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.</ArticleTitle>
<Pagination>
<MedlinePgn>30-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.3324/haematol.2011.045997</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This phase I trial was conducted to determine the safety and pharmacokinetics of monoclonal antibody 216, a human monoclonal Immunoglobulin M antibody targeting a linear B-cell lactosamine antigen, administered alone and in combination with vincristine in patients with relapsed or refractory B-cell acute lymphoblastic leukemia, and to preliminarily assess tumor targeting and efficacy.</AbstractText>
<AbstractText Label="DESIGN AND METHODS" NlmCategory="METHODS">Three cohorts of patients received escalating doses of monoclonal antibody 216 administered as an intravenous infusion. In the case of poor response to the first dose of monoclonal antibody 216 alone, defined as less than 75% reduction in peripheral blood blast count, a second dose of the antibody with vincristine was given between days 4 and 7. Responses were assessed weekly until day 35. Serum concentration of monoclonal antibody 216 was measured before and after infusion. Monoclonal antibody 216 targeting was determined with an anti-idiotypic antibody to monoclonal antibody 216 and preliminary efficacy was analyzed by changes in peripheral blood blasts.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirteen patients were enrolled. One episode of grade 3 epistaxis was the only dose-limiting toxicity observed. All patients showed a poor response to the first monoclonal antibody 216 infusion with a decrease in peripheral blasts from 6-65% in 9 patients. In 8 patients, addition of vincristine to monoclonal antibody 216 resulted in an average reduction of the peripheral blasts of 81%. One patient without peripheral blasts achieved a hypoplastic marrow without evidence of leukemia after one infusion of monoclonal antibody 216 and monoclonal antibody 216/vincristine each. Monoclonal antibody 216 was detected on peripheral blasts in all patients.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Treatment with monoclonal antibody 216 in combination with vincristine is feasible and well tolerated in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Binding of monoclonal antibody 216 to leukemic blasts was efficient, and favorable early responses were observed.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Liedtke</LastName>
<ForeName>Michaela</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, USA. mliedtke@stanford.edu</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Twist</LastName>
<ForeName>Clare J</ForeName>
<Initials>CJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Medeiros</LastName>
<ForeName>Bruno C</ForeName>
<Initials>BC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gotlib</LastName>
<ForeName>Jason R</ForeName>
<Initials>JR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Berube</LastName>
<ForeName>Caroline</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bieber</LastName>
<ForeName>Marcia M</ForeName>
<Initials>MM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Bhat</LastName>
<ForeName>Neelima M</ForeName>
<Initials>NM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Teng</LastName>
<ForeName>Nelson N</ForeName>
<Initials>NN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Coutre</LastName>
<ForeName>Steven E</ForeName>
<Initials>SE</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>K08 CA120349</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R03 CA085199</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>K08CA120349</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R03 CA85199</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2011</Year>
<Month>10</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Italy</Country>
<MedlineTA>Haematologica</MedlineTA>
<NlmUniqueID>0417435</NlmUniqueID>
<ISSNLinking>0390-6078</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000936">Antigen-Antibody Complex</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>5J49Q6B70F</RegistryNumber>
<NameOfSubstance UI="D014750">Vincristine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000911">Antibodies, Monoclonal</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D057134">Antibodies, Neutralizing</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000936">Antigen-Antibody Complex</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000970">Antineoplastic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000493">pharmacokinetics</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004912">Erythrocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054198">Precursor Cell Lymphoblastic Leukemia-Lymphoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014750">Vincristine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2011</Year>
<Month>10</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2011</Year>
<Month>10</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2012</Year>
<Month>5</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">21993685</ArticleId>
<ArticleId IdType="pii">haematol.2011.045997</ArticleId>
<ArticleId IdType="doi">10.3324/haematol.2011.045997</ArticleId>
<ArticleId IdType="pmc">PMC3248928</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Pediatr Blood Cancer. 2009 Dec;53(6):978-83</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19637330</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2008 Aug 1;26(22):3756-62</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18669463</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer. 2009 Dec 1;115(23):5490-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19708032</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Pediatr Hematol Oncol. 2009 Dec;31(12):936-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19875969</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Leuk Lymphoma. 2009 Dec;50(12):1958-63</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19860603</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Pediatr Blood Cancer. 2010 May;54(5):694-702</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20209646</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):59-68</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11418302</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2001 Dec 15;98(13):3840-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11739194</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2002 Jan 24;346(4):235-42</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11807147</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Leukemia. 2003 Feb;17(2):468-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12592351</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2003 Mar 15;21(6):1167-73</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12637486</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2003 Apr 1;101(7):2870-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12468428</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Immunol Immunother. 2004 Feb;53(2):110-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14564483</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Ann Hematol. 2004;83 Suppl 1:S127-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15124704</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 1991 Nov 1;78(9):2372-86</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1657249</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Transfus Med Rev. 1989 Apr;3(2):140-66</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2520550</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Immunol. 1992 Jul;22(7):1781-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1623923</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hum Antibodies Hybridomas. 1992 Jul;3(3):114-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1382650</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur J Immunol. 1994 Dec;24(12):2941-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7805720</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Exp Immunol. 1996 Jul;105(1):183-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8697629</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Exp Immunol. 1997 Apr;108(1):151-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9097924</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2005 Oct 20;353(16):1673-84</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16236738</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2005 Nov 1;23(31):7942-50</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16258094</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2006 Jan 12;354(2):166-78</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16407512</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2006 Dec 20;24(36):5750-62</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17179109</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2007 Feb 1;109(3):944-50</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17032921</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Pediatr Blood Cancer. 2007 Apr;48(4):380-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16421902</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4448-55</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17671129</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Hematol Oncol Clin North Am. 2009 Oct;23(5):949-71, v</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19825447</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>